Tiziana Completes Patient Dosing in Phase 2 Trial of Intranasal Foralumab for Alzheimer’s
Event summary
- Tiziana Life Sciences has dosed the last patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer’s disease.
- The trial is evaluating foralumab as both a monotherapy and in combination with lecanemab or donanemab.
- Topline data from the trial is expected in Q1 2027.
- The study focuses on safety, tolerability, neuroinflammation reduction, cognitive function, and biomarker changes.
The big picture
Tiziana’s Phase 2 trial completion marks a critical step in exploring immunomodulation as a complementary approach to existing anti-amyloid therapies for Alzheimer’s. The study’s focus on neuroinflammation aligns with growing recognition of chronic brain inflammation as a key driver of neurodegenerative diseases. Success in this trial could position foralumab as a novel treatment option in a market increasingly focused on combination therapies.
What we're watching
- Clinical Efficacy
- Whether intranasal foralumab can demonstrate meaningful reduction in neuroinflammation and cognitive decline in mild Alzheimer’s patients.
- Combination Therapy
- The potential synergy of foralumab with anti-amyloid therapies like lecanemab and donanemab in slowing disease progression.
- Regulatory Pathway
- The pace at which Tiziana can advance foralumab through subsequent clinical stages and potential approval.
Related topics